Patents by Inventor Robert Chrusciel

Robert Chrusciel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20220281813
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: October 20, 2021
    Publication date: September 8, 2022
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 11198673
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: December 14, 2021
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20190359567
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: February 27, 2019
    Publication date: November 28, 2019
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 10259785
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: April 16, 2019
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20180244614
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: April 11, 2018
    Publication date: August 30, 2018
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 9994521
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: June 12, 2018
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • (S)-enantiomer of mepazine
    Patent number: 9718811
    Abstract: The present invention relates to the (S)-enantiomer of mepazine, its applicability in therapy, a pharmacological composition comprising (S)-mepazine, and processes for the preparation of (S)-mepazine and one of its intermediates.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: August 1, 2017
    Assignees: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ludwig-Maximilians—Universität München
    Inventors: Daniel Krappmann, Daniel Nagel, Florian Schlauderer, Katja Lammens, Karl-Peter Hopfner, Robert A. Chrusciel, Dale L. Kling
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20170037003
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 9, 2017
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 9499532
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: November 22, 2016
    Assignee: eXIthera Pharmaceuticals Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THE (S)-ENANTIOMER OF MEPAZINE
    Publication number: 20160137635
    Abstract: The present invention relates to the (S)-enantiomer of mepazine, its applicability in therapy, a pharmacological composition comprising (S)-mepazine, and processes for the preparation of (S)-mepazine and one of its intermediates.
    Type: Application
    Filed: June 25, 2014
    Publication date: May 19, 2016
    Inventors: Daniel Krappmann, Daniel Nagel, Florian Schlauderer, Katja Lammens, Karl-Peter Hopfner, Robert A. Chrusciel, Dale L. Kling
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20150225389
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 13, 2015
    Applicant: EXITHERA PHARMACEUTICALS INC.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • FLAVIN DERIVATIVES
    Publication number: 20130029980
    Abstract: The present invention relates novel flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives.
    Type: Application
    Filed: April 6, 2011
    Publication date: January 31, 2013
    Inventors: Philip D. G. Coish, Brian R. Dixon, David Osterman, Paul Adrian Aristoff, Manuel Navia, Frank Sciavolino, Stephanie Avola, Nick Baboulas, Thomas R. Belliotti, Angelica Bello, Judd Berman, Robert A. Chrusciel, Bruce R. Evans, Harpreet Kaur, David Moon, Vinh Pham, Andrew Roughton, Phil Wickens, Jeffrey Wilson, Heinrich J. Schostarez
  • FLAVIN DERIVATIVES
    Publication number: 20120295903
    Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
    Type: Application
    Filed: June 30, 2010
    Publication date: November 22, 2012
    Inventors: Kenneth F. Blount, Philip D.G. Coish, Brian R. Dixon, Jayhyuk Myung, David Osterman, Phil Wickens, Stephanie Avola, Nick Baboulas, Angelica Bello, Judd Berman, Harpreet Kaur, David Moon, Vinh Pham, Andrew Roughton, Jeffrey Wilson, Jeffrey A. Leiby, Dennis Underwood, Paul Adrian Aristoff, Heinrich J. Schostarez, Robert A. Chrusciel, Thomas R. Belliotti, Bruce R. Evans, Frank C. Sciavolino, Manuel A. Navia
  • Cyclic sulfone containing retroviral protease inhibitors
    Publication number: 20070015818
    Abstract: The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.
    Type: Application
    Filed: July 5, 2006
    Publication date: January 18, 2007
    Applicants: G.D. Searle & Co. (now G.D. Searle, LLC), Monsanto Company (now Pharmacia Corporation)
    Inventors: Deborah Bertenshaw, Daniel Getman, Robert Heintz, John Talley, Kathryn Reed, Robert Chrusciel, Michael Clare
  • Cyclic sulfone containing retroviral protease inhibitors
    Patent number: 7112683
    Abstract: The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: September 26, 2006
    Assignees: G.D. Searle & Co., Monsanto Company
    Inventors: Deborah E. Bertenshaw, Daniel P. Getman, Robert M. Heintz, John J. Talley, Kathryn L. Reed, Robert A. Chrusciel, Michael Clare
  • Diaminediols for the treatment of Alzheimer's disease
    Patent number: 7067542
    Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: June 27, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Heinrich Josef Schostarez, Robert A. Chrusciel
  • Aza hydroxylated ethyl amine compounds
    Publication number: 20060069264
    Abstract: Disclosed are compounds of formula: and pharmaceutically acceptable salts and esters thereof, useful in treating and/or preventing Alzheimer's disease and other similar diseases, wherein RN, RC, R1, R2 and R20 are defined herein. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Application
    Filed: November 1, 2005
    Publication date: March 30, 2006
    Inventors: Heinrich Schostarez, Robert Chrusciel, Rebecca Centko
  • Statine derivatives for the treatment of Alzheimer's disease
    Publication number: 20050165069
    Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Application
    Filed: March 8, 2005
    Publication date: July 28, 2005
    Inventors: Heinrich Schostarez, Robert Chrusciel
  • Statine derivatives for the treatment of Alzheimer's disease
    Publication number: 20050159459
    Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Application
    Filed: March 8, 2005
    Publication date: July 21, 2005
    Inventors: Heinrich Schostarez, Robert Chrusciel
  • Methods of treating alzheimer's disease
    Publication number: 20050130941
    Abstract: Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of hydrazine compounds of formula (I) wherein the variables R1-R9 are defined herein.
    Type: Application
    Filed: June 7, 2002
    Publication date: June 16, 2005
    Inventors: Heinrich Schostarez, Robert Chrusciel